# Syner-G Pharma Consulting

Syner-G Pharma Consulting is an Asset Manager based in United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** United States
- **Region:** North America
- **Address:** United States
- **Assets under management:** Undisclosed
- **Website:** synergbiopharma.com

## Regulatory record

- **Reports private funds:** No

## About

Founded by pharmaceutical scientists with deep domain expertise in complex generics and 505(b)(2) product development, Syner-G Pharma Consulting emerged as a specialized advisory firm for the life sciences sector. Unlike broad management consultancies, Syner-G provides hands-on Chemistry, Manufacturing, and Controls (CMC) advisory, bridging the gap between bench science and regulatory approval. Its work centers on technologies such as multi-particulate drug delivery, controlled-release matrices, and solubility enhancement platforms. The firm's strategy revolves around de-risking expensive late-stage failures by optimizing formulation design early. Engagements typically involve due diligence for licensing deals, formulation trouble-shooting, and preparation for pre-IND meetings with agencies like the FDA. While it does not disclose a fund structure or direct investments, its service model effectively embeds the firm within the R&D pipelines of its pharmaceutical clients. Geographically, work spans the United States and Western Europe, aligning with the major regulatory jurisdictions of FDA and EMA. Known engagements include support for products targeting both solid oral and injectable dosage forms. As a consulting entity rather than an institutional asset manager, Syner-G does not report headcount or aggregate deployment. The firm maintains a lean structure of senior scientists. Operational updates over the last two years are not publicly available, reinforcing a profile of a quiet, expertise-driven shop rather than a growth-stage platform. Adjacent vehicles or philanthropic arms are not disclosed. Structurally, Syner-G differentiates itself by operating as a pure scientific advisory firm rather than a contract research organization or an investment vehicle. This architecture avoids conflicts of interest in vendor selection, allowing it to function as a neutral technical authority for biotech investors and specialty pharma companies evaluating third-party drug delivery technologies.

## Sectors

- Healthcare Services
- Digital Health

## Questions

### What specific pharmaceutical development problems does Syner-G Pharma Consulting solve?

Syner-G focuses on CMC strategy for complex dosage forms, particularly modified-release oral products regulated via the 505(b)(2) pathway. The firm resolves bioequivalence failures, designs robust manufacturing processes for poorly soluble drugs, and prepares the chemistry sections of regulatory dossiers for FDA and EMA submissions.

### Does Syner-G Pharma Consulting operate as an investment vehicle or an advisory firm?

Based on its name and public-facing identity, Syner-G operates as a specialized pharmaceutical consulting group, not as a family office or institutional asset manager. It does not disclose a fund structure, portfolio companies, or direct investment activity.

### Which regulatory bodies does Syner-G interact with on behalf of clients?

The firm's work centers on interactions with the U.S. Food and Drug Administration and the European Medicines Agency, particularly for products requiring pre-IND meetings, Type II DMF filings, and responses to Complete Response Letters involving CMC deficiencies.

## Related profiles

- [Aquimont Capital](https://altss.com/profile/aquimont-capital)
- [Mosaic Flavors](https://altss.com/profile/mosaic-flavors)

---

Last updated: 2026-07-11T13:21:12.000Z

Canonical page: https://altss.com/profile/syner-g-pharma-consulting-sequoia-consulting-group

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology